BU
BUGDF.US Bumrungrad Hospital PCL DRC
- Market cap
- USD 4.29B
- P/E
- 20.8x
- P/B
- 3.81x
- ROE
- 27.2%
- Dividend yield
- 3.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BUGDF.US undervalued?
Graham numberBUGDF.US trades 87.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bumrungrad Hospital PCL DRC fundamental analysis
No fundamental analysis for Bumrungrad Hospital PCL DRC yet.
Bumrungrad Hospital PCL DRC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bumrungrad Hospital PCL DRC
Bumrungrad Hospital Public Company Limited owns and operates hospitals and healthcare centers in Thailand and internationally. It offers services in the areas of allergy, arrhythmia, behavioural health, breast, home, heart valve, robotic surgery, rehabilitation, spine, pediatrics, colorectal surgery, complex coronary artery intervention, comprehensive sleep, cornea transplant, dental, diagnostic, dialysis, radiology and nuclear medicine, digestive disease, ear, nose, throat,…
Full company profileBumrungrad Hospital PCL DRC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bumrungrad Hospital PCL DRC annual financial statements (THB; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.9B | 18.3B | 18.3B | 18.5B | 12.4B | 12.5B | 20.7B | 25.4B | 25.7B | 25.1B | 24.9B |
| Gross Profit | 7.51B | 7.89B | 8.28B | 8.19B | 4.68B | 4.73B | 9.62B | 12.5B | 13.2B | 12.7B | 12.8B |
| Operating Income | 4.57B | 4.94B | 5.21B | 4.68B | 1.37B | 1.52B | 6.01B | 8.50B | 9.17B | 8.77B | 8.85B |
| EBITDA | 5.73B | 6.13B | 6.38B | 5.89B | 2.72B | 2.77B | 7.17B | 9.74B | 10.5B | 9.84B | 9.91B |
| Net Income | 3.63B | 3.94B | 4.15B | 3.75B | 1.20B | 1.22B | 4.94B | 7.01B | 7.77B | 7.51B | 7.36B |
| EPS | 4.18 | 4.55 | 4.79 | 4.32 | 1.39 | 1.40 | 5.69 | 8.08 | 8.96 | 8.65 | 8.48 |
| Balance Sheet | |||||||||||
| Total Assets | 21.3B | 23.5B | 24.7B | 26.2B | 24.2B | 20.9B | 24.3B | 29.2B | 32.7B | 36.4B | 33.1B |
| Total Liabilities | 6.54B | 6.78B | 6.00B | 5.92B | 5.39B | 3.24B | 4.25B | 5.11B | 4.85B | 5.60B | 5.76B |
| Shareholders' Equity | 14.5B | 16.4B | 18.5B | 20.0B | 18.5B | 17.3B | 19.7B | 23.8B | 27.5B | 30.5B | 27.0B |
| Cash & Short-term Investments | 6.68B | 8.27B | 9.01B | 8.49B | 8.14B | 5.94B | 8.28B | 10.7B | 12.1B | 13.9B | 7.55B |
| Total Debt | 3.69B | 3.69B | 2.68B | 2.51B | 2.61B | 94.4M | 63.3M | 91.1M | 139M | 487M | 419M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 5.17B | 5.24B | 4.73B | 4.90B | 2.26B | 3.56B | 6.21B | 7.09B | 8.67B | 8.51B | 5.30B |
| Capital Expenditure | 2.45B | 1.67B | 893M | 1.89B | 993M | 969M | 1.22B | 1.68B | 1.32B | 1.92B | 2.74B |
| Free Cash Flow | 2.72B | 3.58B | 3.84B | 3.01B | 1.27B | 2.59B | 4.99B | 5.42B | 7.35B | 6.59B | 2.56B |
| Ratios | |||||||||||
| ROE | 25.1% | 24.0% | 22.5% | 18.8% | 6.5% | 7.0% | 25.1% | 29.4% | 28.3% | 24.6% | 27.2% |
| ROA | 17.0% | 16.8% | 16.8% | 14.3% | 5.0% | 5.8% | 20.4% | 24.0% | 23.8% | 20.6% | 22.2% |
| Net Profit Margin | 20.2% | 21.5% | 22.7% | 20.3% | 9.7% | 9.8% | 23.8% | 27.6% | 30.2% | 29.9% | 29.6% |
| Debt to Equity | 0.25x | 0.23x | 0.15x | 0.13x | 0.14x | 0.01x | 0.00x | 0.00x | 0.01x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bumrungrad Hospital PCL DRC dividends
- Dividend yield
- 3.25%
- Forward dividend
- 0.15 USD
- Payout ratio
- 52.9%
- Ex-dividend date
- Aug 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | THB 3.97B | 4.58 | 52.9% |
| 2024 | THB 4.10B | 4.73 | 52.8% |
| 2023 | USD 2.94B | 3.39 | 41.9% |
| 2022 | USD 2.54B | 2.93 | 51.5% |
| 2021 | USD 2.54B | 2.93 | 209.3% |
| 2020 | USD 2.54B | 2.93 | 211.3% |
| 2019 | USD 2.15B | 2.48 | 57.4% |
| 2018 | USD 2.04B | 2.35 | 49.2% |
| 2017 | USD 1.86B | 2.14 | 47.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on May 24, 2004.
Who owns Bumrungrad Hospital PCL DRC
- Insiders 0.00%
- Institutions 9.68%
- Public & others 90.32%
- Shares outstanding 795M
- Free float 707M
Bumrungrad Hospital PCL DRC company profile
- Company name
- Bumrungrad Hospital PCL DRC
- Ticker
- BUGDF.US
- ISIN
- TH0168010R13
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- December
- Address
- 33 Sukhumvit Soi 3 (Nana Nua), Bangkok, Thailand, 10110
- Phone
- 66 2 066 8888
- Website
- bumrungrad.com
About Bumrungrad Hospital PCL DRC
Bumrungrad Hospital Public Company Limited owns and operates hospitals and healthcare centers in Thailand and internationally. It offers services in the areas of allergy, arrhythmia, behavioural health, breast, home, heart valve, robotic surgery, rehabilitation, spine, pediatrics, colorectal surgery, complex coronary artery intervention, comprehensive sleep, cornea transplant, dental, diagnostic, dialysis, radiology and nuclear medicine, digestive disease, ear, nose, throat, emergency, endocrinology, esperance, diabetes, expatriate liaison, eye, fertility, gastrointestinal motility, health screening, holistic wound care, horizon regional cancer, hyperbaric oxygen therapy, nephrology, neuroscience, orthopaedics, perinatal, plastic surgery, pulmonary, refractive surgery, memory, robotic scoliosis, skin, sports medicine and joint, surgery, travel medicine, urology, scientific wellness, skin and aesthetic, and women's centers. The company also operates breastfeeding, Yangon, COVID-19 recovery, IVF, hearing and balance, medical, new life healthy aging, Parkinson's disease and movement disorders, pride, surgery, and vaccine clinics and centers. In addition, it operates spine institute, heart institute, and intensive care unit; and offers nutrition services, pharmacy services, preventive genomics and integrative medicine services. Bumrungrad Hospital Public Company Limited was founded in 1975 and is based in Bangkok, Thailand.
Bumrungrad Hospital PCL DRC management
10- Dr. Artirat Charukitpipat Ph.D.Chief Executive Officer · born 1968
- Ms. Linda LisahapanyaPresident, MD & Executive Director · born 1953
- Ms. Oraphan Buamuang CPAChief Financial Officer · born 1974
- Ms. Supawan SirinuntawitAccounting Manager
- Dr. Polakit Teekakirikul M.D.Chief Science Officer
- Mr. Daniel KastnerChief Transformation Office & Head of IR
- Dr. Aniello M. Sorrentino Ph.D.Corporate Chief Strategy Officer · born 1948
- Tanee ManeenutChief Business Development Officer
- Dr. Taveesin Tanprayoon M.D.Chief Medical Officer
- Ms. Rangsima ThongdeeHead of Internal Audit